Physician profile
Norbert Moskovits
NPI 1497713879
$159,425.45
in general payments reported to CMS, 2019-2025
30 companies · $267 in 2025
The $267 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $52K · 2020: $13K · 2021: $18K · 2022: $32K · 2023: $33K · 2024: $11K · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39K · Food and Beverage: $2,774 · Consulting Fee: $1,500 · Travel and Lodging: $475 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $38,740.00 |
| Food and Beverage | $2,773.50 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $475.00 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $62,245.00 | 2021-2024 | Verquvo |
| Novartis Pharmaceuticals Corporation | $60,644.61 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $29,119.55 | 2019-2024 | Farxiga, Brilinta |
| Cvrx, INC. | $2,203.58 | 2021-2023 | Barostim Neo System |
| Abbott Laboratories | $1,452.01 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit, Mitraclip |
| Pfizer INC. | $648.16 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $595.65 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $517.52 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $383.95 | 2019-2022 | |
| Amgen INC. | $272.27 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $266.22 | 2019-2022 | |
| Abiomed | $175.00 | 2023 | Impella |
| Irhythm Technologies, INC. | $153.72 | 2019-2022 | |
| Gilead Sciences, INC. | $108.77 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $98.99 | 2023 | Uptravi, Opsumit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $72.99 | 2021-2023 | Amvuttra |
| Vifor Pharma, INC. | $56.81 | 2019-2021 | |
| Atricure, INC. | $54.88 | 2023 | |
| Boston Scientific Corporation | $53.64 | 2020-2023 | Watchman Access System, Watchman |
| Impulse Dynamics (USA) INC. | $47.53 | 2023 | Optimizer |
| Amarin Pharma, INC. | $42.54 | 2019-2020 | |
| Kiniksa Pharmaceuticals, Ltd. | $42.37 | 2023 | Arcalyst |
| Daiichi Sankyo INC. | $34.99 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.12 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $24.77 | 2023 | Inpefa |
| Cook Medical LLC | $23.02 | 2025 | Zenith Alpha |
| E.R. Squibb & Sons, L.L.C. | $22.05 | 2024 | Camzyos |
| Chiesi USA, INC. | $20.22 | 2019 | |
| Astellas Pharma US INC | $15.52 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norbert Moskovits listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.